Navigation Links
Novira Therapeutics Completes $25 Million Series A Financing
Date:3/25/2013

DOYLESTOWN, Pa., March 25, 2013 /PRNewswire/ -- Novira Therapeutics, Inc. today announced the completion of its Series A financing after securing $7.5 million from new investor Versant Ventures. This brings the total raised from all investors in the round to $25 million. Versant joins 5AM Ventures and Canaan Partners, which led the first closing of the Series A in August 2012. In conjunction with this investment, Gianni Gromo M.D ., Ph.D., venture partner with Versant Ventures, joined the company's board of directors.

"We believe the addition of Versant bolsters an already strong investor syndicate," said Osvaldo Flores , Ph.D., president and chief scientific officer of Novira. "We also welcome Gianni to our board and believe his extensive industry experience will contribute greatly to our future success. We plan to use these funds to advance development of our hepatitis B virus (HBV) capsid inhibitor lead program toward the clinic and to discover additional HBV drug candidates."

Dr. Gromo added, "Novira's innovative HBV capsid inhibitor program and the company's highly experienced management team made this an attractive investment for Versant. We believe that Novira's approach to HBV capsid inhibition may disrupt pathways involved in virus persistence and has the potential to produce treatments that can cure millions of patients worldwide who are living with chronic HBV infection."

About Hepatitis B

More than 2 billion people worldwide have been infected with HBV at some time in their lives. Adults with a healthy immune system are capable of clearing HBV infection, but newborns, young children and immunocompromised patients frequently become chronically infected. Approximately 400 million people worldwide suffer from chronic HBV infection, with a significant percentage of those individuals dying from long-term complications such as liver cirrhosis or liver cancer. Treatment with nucleotide/nucleoside analogs can effectively suppress viral replication and delay progression of liver disease but does do not typically lead to a sustained virologic response or cure.

About Versant Ventures

Versant Ventures is a leading venture capital firm that specializes in investments in innovative biopharmaceuticals, medical devices and other life science opportunities. Founded in 1999, the firm consists of an experienced team of managing directors committed to helping entrepreneurs build successful companies that impact healthcare and improve quality of life. The firm's successful IPOs include Clovis Oncology, Jazz Pharmaceuticals, Genomic Health, Insulet and Kythera. M&A exits include Amira, LenSX, Acclarent, Cameron Health Ablation Frontiers and Lutonix. In addition to an industry-leading biotech-focused team in Basel, Switzerland and the San Francisco Bay Area, Versant has a presence in two other key geographic locations of Southern California and Minnesota.

For more information visit versantventures.com.

About Novira Therapeutics

Novira Therapeutics, Inc. is focused on the discovery of first-in-class antiviral therapeutics for the treatment of chronic HBV infection, a global disease with a high level of unmet medical need. Novira's oral drugs target the capsid of the virus and offer a promising treatment option both as monotherapy and in combination with current standards of care. The company's antivirals potentially address limitations in treating chronic HBV infection, a disease for which the only class of oral drugs available, polymerase inhibitors is rarely curative despite lifelong treatment. Capsid inhibitors that feature a new mechanism of action may address the limitations in the effectiveness of HBV therapy.

For more information, visit www.noviratherapeutics.com.

Contacts:

Corporate Contact
Osvaldo Flores , Ph.D.
President, CSO
lflores@noviratherapeutics.com

Media Contacts
David Schull                           
Matt Middleman, M.D.                                   
Russo Partners                                              
T: 212-845-4271                                
T: 212-845-4272
david.schull@russopartnersllc.com
matt.middleman@russopartnersllc.com


'/>"/>
SOURCE Novira Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Peptide Therapeutics Market is Expected to Reach USD 25.4 Billion Globally in 2018: Transparency Market Research
2. Pain Therapeutics - Drugs, Markets and Companies - 2013 Report
3. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
4. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
5. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
6. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
7. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
8. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
9. United Therapeutics Announces Additional $420 Million Share Repurchase Program
10. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
11. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017  Trovagene, Inc. (NASDAQ: TROV), a ... Executive Officer, Bill Welch , will be presenting ... at 9:00 AM EDT at the Essex House in ... and Chief Scientific Officer, Mark Erlander , Ph.D., ... the conference.   The presentation will be webcast ...
(Date:3/27/2017)... 27, 2017 Neurotrope, Inc. (OTCQB: NTRP),  ... neurodegenerative diseases, including Alzheimer,s disease, today announced that ... list the Company,s common stock on the NASDAQ ... Stock Market, a unit of the NASDAQ OMX ... the Opening Bell at the NASDAQ MarketSite in ...
(Date:3/24/2017)... Md. , March 24, 2017  Infectex Ltd., ... (MBVF), today announced positive results of a Phase 2b-3 ... therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). ... scientists at Sequella, Inc. ( USA ) ... A total of 140 patients were enrolled in ...
(Date:3/24/2017)... 2017 Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... , today announced that its board of directors has amended ... plan from March 27, 2017 to March 27, 2018. The amendment was ... Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a China ...
Breaking Biology Technology:
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , ... Well Made Simple," and 23andMe , the leading ... better food choices.  Zipongo can now provide customers with ... preferences, health goals and biometrics, but also genetic markers ... choices. Zipongo,s personalized food decision support platform ...
(Date:3/2/2017)... Summary This report provides all the information you ... activities since 2010. ... Read the full report: http://www.reportlinker.com/p03605615-summary/view-report.html ... an in-depth insight into the partnering activity of one of ... company reports are prepared upon purchase to ensure inclusion of ...
(Date:3/1/2017)... 1, 2017  Aware, Inc. (NASDAQ: AWRE), a leading ... Richard P. Moberg has resigned, effective March 3, ... Financial Officer and Treasurer of Aware citing a desire ... a member of the Board of Directors of Aware. ... Executive Officer and co-President, General Counsel has been named ...
Breaking Biology News(10 mins):